In the last trading session, 6,967,903 shares of the Clovis Oncology, Inc.(NASDAQ:CLVS) were traded, and its beta was 1.63. Most recently the company’s share price was $6.65, and it changed around -$0.02 or 0% from the last close, which brings the market valuation of the company to $687.82 Million. CLVS currently trades at a discount to its 52-week high of $11.1, offering almost -66.92% off that amount. The share price’s 52-week low was $3.62, which indicates that the current value has risen by an impressive 45.56% since then. We note from Clovis Oncology, Inc.’s average daily trading volume that its 10-day average is 10.05 Million shares, with the 3-month average coming to 7.63 Million.
Clovis Oncology, Inc. stock received a consensus recommendation rating of Hold, based on a mean score of 3.3. If we narrow it down even further, the data shows that 2 out of 7 analysts rate the stock as a Sell; another but none rate it as Overweight. Among the rest, 3 recommended CLVS as a Hold, whereas 1 deemed it a Buy, and 1 rated it as Underweight. Clovis Oncology, Inc. is expected to report earnings per share of -$0.77 for the current quarter.
Clovis Oncology, Inc. (NASDAQ:CLVS): Trading Information
Although CLVS has showed a red trend with a performance of -0.3% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of $8.60- on Friday, Feb 12 increased the stock’s daily price by 22.67%. The company’s shares are currently up 0.39% year-to-date, but still down -0.2263 over the last five days. On the other hand, Clovis Oncology, Inc. (NASDAQ:CLVS) is 0.09% up in the 30-day period. We can see from the shorts that 36.09 Million shares have been sold at a short interest cover period of 4.73 day(s).
The consensus price target as assigned by Wall Street analysts is $7, which translates to bears needing to increase their stock price by 5.26% from its current value. Analyst projections state that CLVS is forecast to be at a low of $3 and a high of $15. In order for the stock price to hit the forecast high, the stock would need to surge +125.56% from its current level, while the stock would need to crash -54.89% from its current level to reach the projected low.
Clovis Oncology, Inc. (CLVS) projections and forecasts
Clovis Oncology, Inc. share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen +21.68 percent over the past six months and at a 45.09% annual growth rate that is well above the industry average of 14%. Moreover, analysts have decided to roll up on their fiscal year 2021 revenue estimates. The rating firms predict that it will gain +57.5% in revenue this quarter, and will report an increase of 49.6% in the next quarter. The year-over-year growth rate is expected to be 15%, up from the previous year.
Consensus estimates provided by 6 financial analysts predict the company will bring in an average of $43.22 Million in revenue for the current quarter. 4 analysts expect Clovis Oncology, Inc. to make $43.9 Million in revenue for the quarter ending March 01, 2021. The company’s sales for the same quarters a year ago were $39.31 Million and $42.56 Million respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 10%. Forecasts for the next quarter put sales growth at 3.1%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -9.5%. Clovis Oncology, Inc. earnings are expected to decrease by -5.2% in 2021, but the outlook is positive 78.9% per year for the next five years.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Clovis Oncology, Inc. (NASDAQ:CLVS)’s Biggest Investors
Upon looking at major shareholders, it appears that insiders hold 2.08% of Clovis Oncology, Inc. shares, and 60.69% of them are in the hands of institutional investors. The stock currently has a share float of 61.98%. Clovis Oncology, Inc. stock is held by 228 institutions, with State Street Corporation being the largest institutional investor. By Sep 29, 2020, it held 10.92% of the shares, which is about 9.65 Million shares worth $56.24 Million.
Blackrock Inc., with 7.75% or 6.85 Million shares worth $32.86 Million as of Dec 30, 2020, holds the second largest percentage of outstanding shares.